TP53 and ovarian serous adenocarcinoma: Interestingly, our analysis suggest that in serous ovarian cancer patients with TP53 mutations, high BDP1 expression is unfavorable for overall survival, n = 111; p = 2.7 × 10−4; Hazard Ration (HR) = 2.11, with a 2% FDR (Figure 4A), is unfavorable for overall survival in stages II and III, n = 91; p = 0.0013; HR = 2.09, 5% FDR (Figure 4C), and III and IV n = 107; p = 0.0012; HR = 1.96, 5% FDR (Figure 4D).